199 related articles for article (PubMed ID: 35176476)
1. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
Aslan AT; Kırbaş E; Sancak B; Tanrıverdi ES; Otlu B; Gürsoy NC; Yılmaz YA; Tozluyurt A; Liste Ü; Bıçakcıgil A; Hazırolan G; Dağ O; Güven GS; Akova M;
Int J Antimicrob Agents; 2022 Apr; 59(4):106554. PubMed ID: 35176476
[TBL] [Abstract][Full Text] [Related]
2. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan.
Su CF; Chuang C; Lin YT; Chan YJ; Lin JC; Lu PL; Huang CT; Wang JT; Chuang YC; Siu LK; Fung CP
Eur J Clin Microbiol Infect Dis; 2018 Apr; 37(4):651-659. PubMed ID: 29238934
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC
Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology, mortality and risk factors for patients with K. pneumoniae bloodstream infections: Clinical impact of carbapenem resistance in a tertiary university teaching hospital of Beijing.
Zhang G; Zhang M; Sun F; Zhou J; Wang Y; Zhu D; Chen Z; Chen Q; Chang Q; Liu H; Chai W; Pan H
J Infect Public Health; 2020 Nov; 13(11):1710-1714. PubMed ID: 33082112
[TBL] [Abstract][Full Text] [Related]
6. Molecular Epidemiology and Risk Factors of Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections in Wuhan, China.
Liu C; Liu L; Jin MM; Hu YB; Cai X; Wan L; Zhang HY; Li RY; Wu XJ
Curr Med Sci; 2022 Feb; 42(1):68-76. PubMed ID: 34985611
[TBL] [Abstract][Full Text] [Related]
7. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Vieceli T; Henrique LR; Rech TH; Zavascki AP
J Infect Chemother; 2024 Jul; 30(7):621-625. PubMed ID: 38244722
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.
Xiao T; Zhu Y; Zhang S; Wang Y; Shen P; Zhou Y; Yu X; Xiao Y
J Infect Dis; 2020 Mar; 221(Suppl 2):S174-S183. PubMed ID: 32176799
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae bacteraemia in children: a retrospective study.
Meng H; Yang J; Niu M; Zhu H; Zhou Y; Lu J
Int J Antimicrob Agents; 2023 Oct; 62(4):106933. PubMed ID: 37500022
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
[TBL] [Abstract][Full Text] [Related]
11. Mortality-related factors in patients with OXA-48 carbapenemase-producing Klebsiella pneumoniae bacteremia.
Rodríguez OL; Sousa A; Pérez-Rodríguez MT; Martínez-Lamas L; Suárez RL; Martínez CT; Pino CP; Vidal FV; Pérez-Landeiro A; Casal MC
Medicine (Baltimore); 2021 Apr; 100(14):e24880. PubMed ID: 33832068
[TBL] [Abstract][Full Text] [Related]
12. Healthcare-associated carbapenem-resistant Klebsiella pneumoniae bloodstream infections: Risk factors, mortality, and antimicrobial susceptibility, 2017-2019.
Hsu JY; Chuang YC; Wang JT; Chen YC; Hsieh SM
J Formos Med Assoc; 2021 Nov; 120(11):1994-2002. PubMed ID: 33962811
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of OXA-48 carbapenemase-producing Klebsiella pneumoniae infection in a tertiary-care Spanish hospital: A retrospective single-center cohort study.
Corbella L; Fernández-Ruiz M; Ruiz-Ruigómez M; Rodríguez-Goncer I; Silva JT; Hernández-Jiménez P; López-Medrano F; Lizasoain M; Villa J; Carretero O; Aguado JM; San-Juan R
Int J Infect Dis; 2022 Jun; 119():59-68. PubMed ID: 35331934
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and outcomes of carbapenemase harbouring carbapenem-resistant Klebsiella spp. bloodstream infections: a multicentre prospective cohort study in an OXA-48 endemic setting.
Isler B; Özer B; Çınar G; Aslan AT; Vatansever C; Falconer C; Dolapçı İ; Şimşek F; Tülek N; Demirkaya H; Menekşe Ş; Akalin H; Balkan İİ; Aydın M; Tigen ET; Demir SK; Kapmaz M; Keske Ş; Doğan Ö; Arabacı Ç; Yağcı S; Hazırolan G; Bakır VO; Gönen M; Chatfield MD; Forde B; Saltoğlu N; Azap A; Azap Ö; Akova M; Paterson DL; Can F; Ergönül Ö
Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):841-847. PubMed ID: 35301623
[TBL] [Abstract][Full Text] [Related]
15. External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance.
Machuca I; Gutiérrez-Gutiérrez B; Rivera-Espinar F; Cano A; Gracia-Ahufinger I; Guzman-Puche J; Marfil-Pérez E; Pérez-Nadales E; Castón JJ; Bonomo RA; Carmeli Y; Paterson D; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J;
Int J Antimicrob Agents; 2019 Oct; 54(4):442-448. PubMed ID: 31377343
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study.
Wang M; Earley M; Chen L; Hanson BM; Yu Y; Liu Z; Salcedo S; Cober E; Li L; Kanj SS; Gao H; Munita JM; Ordoñez K; Weston G; Satlin MJ; Valderrama-Beltrán SL; Marimuthu K; Stryjewski ME; Komarow L; Luterbach C; Marshall SH; Rudin SD; Manca C; Paterson DL; Reyes J; Villegas MV; Evans S; Hill C; Arias R; Baum K; Fries BC; Doi Y; Patel R; Kreiswirth BN; Bonomo RA; Chambers HF; Fowler VG; Arias CA; van Duin D;
Lancet Infect Dis; 2022 Mar; 22(3):401-412. PubMed ID: 34767753
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of carbapenem-resistant
Wang Y; Lei H; Zhang Y; Yang Q; Wang Y; Wang J; Xu C; Yu J; Zhou L; Kang X; Cui L
Antimicrob Resist Infect Control; 2018; 7():66. PubMed ID: 29942492
[TBL] [Abstract][Full Text] [Related]
18. [Klebsiella pneumoniae Infections in the Intensive Care Unit: Risk Factors Related to Carbapenem Resistance and Patient Mortality].
Büyüktuna SA; Hasbek M; Çelik C; Ünlüsavuran M; Avcı O; Baltacı S; Fırtına Topcu K; Elaldı N
Mikrobiyol Bul; 2020 Jul; 54(3):378-391. PubMed ID: 32755515
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients.
Zhang Y; Guo LY; Song WQ; Wang Y; Dong F; Liu G
BMC Infect Dis; 2018 May; 18(1):248. PubMed ID: 29855274
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and molecular epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae.
Zhu Q; Xu J; Chen X; Ren Y; Zhao L
Diagn Microbiol Infect Dis; 2023 Jul; 106(3):115955. PubMed ID: 37167651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
